Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer

Donglai Chen,Yiming Mao,Yongbing Chen,Chang Chen

DOI: https://doi.org/10.1016/j.jtho.2020.06.023

IF: 20.121

2020-01-01

Journal of Thoracic Oncology

Abstract:We would like to comment on the recently published article entitled “Survival After Mediastinal Node Dissection, Systematic Sampling or Neither for Early-Stage Non-Small Cell Lung Cancer” in the Journal of Thoracic Oncology. Ray et al.1Ray M.A. Smeltzer M.P. Faris N. Osarogiagbon R.U. Survival after mediastinal node dissection, systematic sampling or neither for early-stage non-small-cell lung cancer [e-pub ahead of print]. J Thorac Oncol.https://doi.org/10.1016/j.jtho.2020.06.009Google Scholar performed an interesting study regarding types of nodal evaluation in patients with clinical-stage T1-2N0-1M0 in different institutions and found that mediastinal nodal dissection was associated with superior survival over the less-comprehensive pathologic nodal staging in teaching institutions. However, we have some concerns. First, as illustrated in Table 1 of this study, the authors presented a heterogeneous cohort in which the patients underwent mediastinal nodal dissection, systematic sampling, or neither sampling method. However, the authors did not provide information on patients with different radiologic features such as ground-glass opacity (GGO). It had been reported that lymphadenectomy is unnecessary for patients with pulmonary nodules presenting as pure GGO.2Lin Y.H. Chen C.K. Hsieh C.C. et al.Lymphadenectomy is unnecessary for pure ground-glass opacity pulmonary nodules.J Clin Med. 2020; 9: 672Crossref Scopus (8) Google Scholar Furthermore, the occurrence of lymph node metastasis is rare in part-solid pulmonary nodules.3Ye T. Deng L. Wang S.P. et al.Lung adenocarcinomas manifesting as radiological part-solid nodules define a special clinical subtype.J Thorac Oncol. 2019; 14: 617-627Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar Thus, the proportion of patients with nodules presenting as GGO could have probably affected the comparability of the three groups if stratified by different nodal evaluation methods. Second, with regard to the different numbers of stations examined in the three groups, the authors did not mention the difference in lymph node yields among the three groups. It must be noted that the number of lymph nodes harvested was identified as an independent prognosticator in several studies, even in stage I disease.4Dai J. Liu M. Yang Y. et al.Optimal lymph nodes examination and adjuvant chemotherapy for stage I lung cancer.J Thorac Oncol. 2019; 14: 1277-1285Abstract Full Text Full Text PDF PubMed Scopus (23) Google Scholar,5Liang W. He J. Shen Y. et al.Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry.J Clin Oncol. 2017; 35: 1162-1170Crossref PubMed Scopus (133) Google Scholar In addition, the authors did not include lymph node yields in their Cox proportional hazards models. Although the authors explicated the inclusion of nodal stations in the three groups, they did not mention the manner of retrieval and identification of intrapulmonary nodes in the resected specimens, which should have been detailed whenever possible. Third, it is regrettable that the authors did not reveal any data on adjuvant treatment in Table 1. This left us wondering how many patients were diagnosed as stage IB or more advanced stages, of whom the majority might benefit from adjuvant chemotherapy.4Dai J. Liu M. Yang Y. et al.Optimal lymph nodes examination and adjuvant chemotherapy for stage I lung cancer.J Thorac Oncol. 2019; 14: 1277-1285Abstract Full Text Full Text PDF PubMed Scopus (23) Google Scholar,6Zhang T. Guo Q. Zhang Y. Liu Z. Zhou S. Xu S. Meta-analysis of adjuvant chemotherapy versus surgery alone in T2aN0 stage IB non-small cell lung cancer.J Cancer Res Ther. 2018; 14: 139-144Crossref PubMed Scopus (6) Google Scholar,7Wang J. Wu N. Chao L. Yan S. Yang Y. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.J Cancer Res Clin Oncol. 2019; 145: 463-469Crossref PubMed Scopus (10) Google Scholar In addition, the authors did not include adjuvant treatment in their Cox proportional hazards models, which might have caused potential bias. To sum up, the aforementioned points should be addressed before interpreting the results in clinical practice. The work was supported by the projects from Suzhou Key Laboratory of Thoracic Oncology (SZS201907), Suzhou Key Discipline for Medicine (SZXK201803), Municipal Program of People's Livelihood Science and Technology in Suzhou (SS2019061), and Jiangsu Key Research and Development Plan (Social Development) Project (BE2020653). Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLCJournal of Thoracic OncologyVol. 15Issue 10PreviewThe American College of Surgeons Oncology Group Z0030 found no survival difference between patients with early stage NSCLC who had mediastinal nodal dissection or systematic sampling. However, a meta-analysis of 1980 patients in five randomized controlled trials from 1989 to 2007 associated better survival with nodal dissection. We tested the survival impact of the extent of nodal dissection in curative-intent resections for early stage NSCLC in a population-based observational cohort. Full-Text PDF Open Archive